

'Diabetes Asia 2014' Conference

Organised by

NADI NATIONAL
DIABETES
INSTITUTE
CENTRE OF EXCELLENCE DEDICATED TO DIABETICS

Endorsed by



Ministry of Health Malaysia



October 16 – 19, 2014
Sunway Pyramid Convention Centre
Selangor, Malaysia



ABSTRACTS / FREE PAPER PRESENTATION

13th Continuing Professional Development (CPD) Series

CONFERENCE AWARDS

"Prof Mustaffa
Young Investigators Awards"

"Oral Presentation Awards"

"Poster Presentation Awards"

Platinum Sponsor



Secretariat 'DIABETES ASIA 2014' Conference
National Diabetes Institute (NADI)

No. 1, Jalan SS 3/50, 47300 Petaling Jaya, Selangor, MALAYSIA.
Tel: +603-7876 1676 / 7876 1677 Fax: +603-7876 1679

Email: enquiry@nadidiabetes.com.my Website: www.diabetesmalaysia.com.my

Official Media Partner

CORPORATE 21

- 8 **KNOWLEDGE, ATTITUDE AND PRACTISE (KAP) ON INSULIN INJECTION AMONG TYPE 2 DIABETES MELLITUS PATIENTS IN HRPZ II: CONVENTIONAL COUNSELING VERSUS MULTIMEDIA-AIDED COUNSELING.**
Ms. Norsilawati Binti Ramli, Hospital Raja Perempuan Zainab II, Kelantan
- 9 **AN EVALUATION ON DIABETES MELLITUS PATIENTS' PROFILE AND MANAGEMENT IN DIABETIC CLINIC, HOSPITAL TUANKU JAA'FAR SEREMBAN FOR JUNE, YEAR 2014**
Dr. Yong Lit Sin, Hospital Tuanku Jaafar, Negeri Sembilan
- 10 **IN VIVO AND IN VITRO ANTIDIABETIC STUDIES OF PERESKIA BLEO LEAVES**
Dr. Qamar Uddin Ahmed, International Islamic University Malaysia, Pahang
- 11 **EFFECTIVENESS OF EMPOWER-PAR INTERVENTION ON PRIMARY CARE PROVIDERS' ADHERENCE TO CLINICAL PRACTICE GUIDELINES IN MANAGING PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PRAGMATIC CLUSTER RANDOMISED CONTROLLED TRIAL**
Dr. Maryam Hannah Daud, University Technology MARA, Selangor
- 12 **PREVALENCE OF DIASTOLIC DYSFUNCTION AMONGST TYPE 2 DIABETES MELLITUS SUBJECTS IN THE COMMUNITY**
Dr. Sharifah Faradila WM Hatta, University Malaya Medical Centre, Selangor
- 13 **FACTORS ASSOCIATED WITH POOR GLYCEMIC CONTROL AMONG PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES AT A PRIMARY CARE SETTING**
Ms. Tai Chia Woon, Mahmoodiah Health Clinic, Johor Bahru, Johor
- 14 **EFFECTIVENESS OF EMPOWER-PAR INTERVENTION ON PRIMARY CARE PROVIDERS' PRESCRIBING OF ANTI-DIABETIC, ANTI-HYPERTENSIVE, AND LIPID LOWERING AGENTS AMONG TYPE 2 DIABETIC PATIENTS: A PRAGMATIC CLUSTER RANDOMISED CONTROLLED TRIAL**
Ms. Nur Khairul Bariyyah Mohd Hatta, National Clinical Research
- 15 **TYPE 2 DIABETES MELLITUS CARE BASED ON HBA1C IN JOHOR STATE FOR 4 YEARS (2010-2013)**
Dr. Mawaddah Binti Abdul Malik, Johor State Health Department, Johor
- 16 **OUTCOME OF THE SCREENING FOR DIABETIC COMPLICATIONS IN INTEGRATED DIABETIC CLINICS FOR 9 HOSPITALS IN KEDAH STATE (COHORT 2014)**
Dr. Ng Yen Kim, Kedah State Health Department, Kedah
- 17 **PROSPECTS OF FULLERENE (C60) IN AMPLIFYING THE SENSITIVITY OF NEW GENERATION NONINVASIVE DIABETES BIOSENSORS BASED ON VOC DETECTION TECHNIQUE**
Ms. Sadia Afreen, The University of Nottingham, Malaysia Campus, Semenyih

Date : 16th – 18th October 2014 (Thursday - Saturday)
Time : 0915 – 0945- Coffee Break
1300 – 1400 - Lunch Break
1600 – 1630 - Tea Break
Venue : Foyer Pyramid
Chief : Professor Dato' Anuar Zaini Md Zain, Monash University Malaysia
Head Judge : Dr. Zanariah Hussein, Putrajaya Hospital
Judging Panel : Professor Z. Sehnaz Karadeniz, TURKEY
: Associate Professor Muhammad Yazid Jalaludin, University Malaya
Medical Centre
: Datuk Dr. Mohamed Badrulnizam Long Bidin, Kuala Lumpur Hospital

POSTER NO. 10

IN VIVO AND IN VITRO ANTIDIABETIC STUDIES OF PERESKIA BLEO LEAVES

Qamar Uddin Ahmed^{1*}, Zufadzliza Binti Ahmad², Mehnaz Afrin³, Tasnuva Sarwar Tunna⁴, Nur Amalina Binti Ibrahim Apanidi², Wan Norshakirah Binti Wan Zaini²

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy

²Department of Biomedical Science, Faculty of Science

³Department of Basic Medical Sciences, Faculty of Pharmacy

⁴Department of Pharmaceutical Technology, Faculty of Pharmacy

International Islamic University Malaysia, 25200 Kuantan, Pahang DM, Malaysia

*Email: quahmed@iiu.edu.my

Background review

Since ancient times, plants have been used as natural agents to treat diseases particularly diabetes whose prevalence is increasing worldwide. Leaves of *Pereskia bleo* (Jarum Tujuh Bilah) are traditionally used to treat diabetes in many countries including Malaysia, however, no scientific claim exists in literature.

Objective

To investigate *in vivo* and *in vitro* antidiabetic activity of *P. bleo* with respect to understand its role in the management of diabetes.

Methods

Freeze dried aqueous (AQ) and ethanol (ETOH) extracts of the leaves were examined for *in vivo* antidiabetic activity (alloxan induced diabetic adult albino male rats of Sprague Dawley strain) and *in vitro* activity (inhibition of alpha-glucosidase and alpha-amylase enzymes). Two doses (250 and 500 mg/kg body weight) of both extracts were administered orally to the normal and diabetic rats. The blood glucose level of the rats was measured by using glucometer at 0, 2, 4, 6, 8 and 24 h after administering both extracts. For *in vitro* method, the inhibitory activities of both extracts against α -amylase and α -glucosidase were evaluated at 5 different concentrations (i.e. 50, 100, 250, 500, and 1000 μ g/ml). Toxicological study was also performed to know the safe nature of both extracts.

Results and Conclusion

The acute toxicity study revealed LD₅₀ for the both AQ and ETOH extracts above 2500 mg/kg b.w. Both extracts exhibited a significant antihyperglycemic effect in diabetic rats after 24 h treatment of the extracts without showing hypoglycemic effect in normal rats. The highest blood glucose reduction (from 28.3 to 9.0 mmol/l) in diabetic rats was seen in ETOH extract at 250 mg/kg b.w. after 24 h. For *in vitro* antidiabetic study, both extracts showed high inhibitory activity against α -amylase. The highest inhibition (99.23%) was seen at 1000 μ g/mL by AQ extract. On the other hand, AQ extract did not show inhibitory activity against α -glucosidase and ETOH showed a moderate inhibition (15.46%) against α -glucosidase at 1000 μ g/mL. The results from this study further justify the traditional claims of *P. bleo* in the management of diabetes in Malaysia.